Tyrosine — an amino acid that the body uses to synthesize dopamine, norepinephrine, and epinephrine — is widely sold as a cognitive enhancement supplement. The marketing premise is simple: more tyrosine means more dopamine precursor, which means better focus and mental performance. Millions of people take it daily.
Researchers at the University of Hong Kong and the University of Georgia analyzed data from over 270,000 people in the UK Biobank, using both observational analysis and Mendelian randomization — a technique that uses natural genetic variants as proxies for exposure, providing evidence about causal direction that observational studies cannot. Higher blood levels of tyrosine were associated with nearly one year shorter lifespan in men. The causal link held under Mendelian randomization. No significant effect was observed in women.
Published in the journal Aging, the finding introduces a specific tradeoff where the supplement literature typically assumes unidirectional benefit. Tyrosine supplementation may improve acute cognitive performance — some studies support this in high-stress conditions. But the mechanism that delivers the short-term benefit may impose a long-term cost. More dopaminergic precursor material means more catecholamine synthesis, which means more oxidative stress from catecholamine metabolism, which means faster cellular damage accumulation.
The structural insight is about hidden taxes on optimization. Tyrosine supplementation optimizes one measurable variable (cognitive performance under stress) while degrading another (lifespan) that is not measured at the point of intervention. The user sees the benefit — better focus — and does not see the cost, because the cost accrues over years or decades and is distributed across the entire body rather than localized in the experience of improved cognition.
This is a general pattern in biological optimization: gains in one parameter often come at the expense of another, but the expense operates on a different timescale or in a different organ system than the gain. The supplement industry's entire value proposition — targeted improvement without systemic cost — assumes these tradeoffs are either absent or negligible. The tyrosine finding suggests they are neither. The sex-specific effect (men only) adds another dimension: the tradeoff exists in some bodies but not others, making population-level recommendations unreliable for individual decisions.